Kane Biotech Inc. (CVE:KNE – Get Free Report) shares reached a new 52-week low on Tuesday . The company traded as low as C$0.03 and last traded at C$0.03, with a volume of 40245 shares changing hands. The stock had previously closed at C$0.04.
Kane Biotech Price Performance
The company has a market capitalization of C$4.99 million, a P/E ratio of -0.33 and a beta of 0.23. The business’s 50-day moving average is C$0.04 and its two-hundred day moving average is C$0.04. The company has a quick ratio of 0.39, a current ratio of 0.80 and a debt-to-equity ratio of -331.42.
Kane Biotech Company Profile
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections.
Recommended Stories
- Five stocks we like better than Kane Biotech
- What is the Shanghai Stock Exchange Composite Index?
- Worried About Mag 7 Concentration Risk? This ETF Could Help
- How to start investing in penny stocks
- Dell Just Hit a Record in AI Orders—But the Real Test Starts Now
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Here’s Who Wins If Trump’s 50-Year Mortgages Come to Market
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
